NetScientific PLC Amendment to Executive Director Service Terms (5200I)
26 Novembro 2018 - 1:01PM
UK Regulatory
TIDMNSCI
RNS Number : 5200I
NetScientific PLC
26 November 2018
NetScientific plc
Amendment to Executive Director Service Terms
London, UK - November 26, 2018 - NetScientific plc
("NetScientific" or the "Company", AIM:NSCI), the transatlantic
healthcare IP commercialisation Company, announces that, in light
of the Company's formal sale process announced earlier today, the
Company has, as approved by its remuneration committee, amended the
service terms of François Martelet (CEO) and Ian Postlethwaite
(CFO) (the "Executive Directors") in order to incentivise these
individuals to remain as Directors and employees of the Company
throughout that process.
Under the amendment to their respective service terms, each
Executive Director will, assuming completion of a transaction at
the end of the formal sale process (a "Transaction"), receive a
bonus, in addition to his existing entitlements, equal to 50 per
cent. of his annual salary in the event that:
1. he receives notice of termination of employment by reason of
redundancy at any time within three months of the completion of any
Transaction;
2. he has not given notice of resignation from his employment,
howsoever arising, prior to the receipt of the notice of
termination referred to above; and
3. upon the termination of his employment, he enters into a
settlement agreement on terms acceptable to the Company.
For the purposes of this amendment to the Executive Directors'
service terms, completion of the Transaction means the conclusion,
by whatever means, of the acquisition of (i) the Company or (ii)
the Company's interest in the majority of its portfolio
companies.
The bonuses payable to François Martelet and Ian Postlethwaite
would amount to GBP123,600 and GBP103,000, respectively, based on
current salary. The amendments to their service terms represent
related party transactions in accordance with AIM Rule 13. The
Independent Directors, being each of the Directors of the Company
other than the Executive Directors, consider, having consulted with
the Company's nominated adviser, that the terms of the amendments
are fair and reasonable insofar as shareholders are concerned.
Commenting on the above, Sir Richard Sykes, Chairman of the
Remuneration Committee, stated:
"We believe that to achieve the best outcome for our
shareholders it is crucial that we retain the services of our key
executives throughout the formal sale process, hence we have
amended their service terms as described above."
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet, M.D., CEO
Ian Postlethwaite, CFO
WHIreland (NOMAD, Financial Adviser and Tel: +44 (0)20 7220 1666
Broker)
Chris Fielding / Jessica Cave / Chris Viggor
Ondra (Financial Adviser) Tel: +44 (0)20 7082 8827
Michael Tory / Michiel Bröker
Consilium Strategic Communications Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Chris Welsh / Laura NetScientific@consilium-comms.com
Thornton
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.NetScientific.net
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFKADDQBDDQDB
(END) Dow Jones Newswires
November 26, 2018 10:01 ET (15:01 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024